European Commission clears acquisition of Anda Distribution by Teva
The European Commission has approved under the EU Merger Regulation the acquisition of Anda Distribution of the USA by Teva Pharmaceutical Industries (NYSE: TEVA) of Israel.
Back in August, Teva entered into a definitive agreement to purchase Allergan’s Anda Inc, the fourth largest distributor of generic pharmaceuticals in the USA for $500 million. The proposed deal came just a day after Teva completed it $40.5 billion purchase of THE Allergan global generics business.
The Commission noted that Anda is a distributor of pharmaceutical products, serving pharmacies, nursing homes, hospitals and clinics in the USA only. Teva is active worldwide in the development, manufacturing, marketing, sale and distribution of pharmaceutical products, biopharmaceuticals and pharmaceutical ingredients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze